跳至主要内容
临床试验/NCT00006119
NCT00006119已完成2 期

Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma

UNICANCER10 个研究点 分布在 1 个国家开始时间: 1999年7月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
UNICANCER
试验地点
10

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent and/or unresectable meningioma.

详细描述

OBJECTIVES:

  • Determine complete, partial, or stable response to hydroxyurea in patients with recurrent and/or nonresectable meningioma.
  • Determine response at 2 years to this regimen in these patients.
  • Determine overall and disease free survival of these patients after this regimen.
  • Determine quality of life of these patients.
  • Determine the toxicities of this regimen in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to grade of disease (I vs II or III).

Patients receive oral hydroxyurea daily for 2 years.

Quality of life is assessed before treatment, then every 3 months for 2 years.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
16 Years 至 120 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
UNICANCER
申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验

Hydroxyurea in Treating Patients With Recurrent... | 临床试验